A Phase III Study of Recombinant Interleukin-2, 5-Fluorouracil and Leucovorin Versus 5-Fluorouracil and Leucovorin in Patients with Unresectable or Metastatic Colorectal Carcinoma

By Heys S.D.   Eremin O.   Ruggeri E.M.   Pein F.   Rainer H.   Oskam R.   de Peuter R.A.   Palmer P.A.   Franks C.R.  

European Journal of Cancer, Vol. 31, Iss. 1, 1995-01 ,pp. : 19-25

Elsevier

Access to resources Recommend Favorite

Doxifluridine in Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU) Containing Regimens

By Bajetta E.   Di Bartolomeo M.   Somma L.   Del Vecchio M.   Artale S.   Zunino F.   Bignami P.   Magnani E.   Buzzoni R.  

European Journal of Cancer, Vol. 33, Iss. 4, 1997-04 ,pp. : 687-690

Elsevier

Access to resources Recommend Favorite

Plasma and Salivary Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer Receiving 5-FU Bolus Plus Continuous Infusion with High-dose Folinic Acid

By Joulia J.M.   Pinguet F.   Ychou M.   Duffour J.   Astre C.   Bressolle F.  

European Journal of Cancer, Vol. 35, Iss. 2, 1999-02 ,pp. : 296-301

Elsevier

Access to resources Recommend Favorite

Oxaliplatin with High-dose Leucovorin and 5-Fluorouracil 48-hour Continuous Infusion in Pretreated Metastatic Colorectal Cancer

By de Gramont A.   Vignoud J.   Tournigand C.   Louvet C.   Andre T.   Varette C.   Raymond E.   Moreau S.   Le Bail N.   Krulik M.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 214-219

Elsevier

Access to resources Recommend Favorite

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil.

By Negrier S.   Caty A.   Lesimple T.   J-Y D.   Escudier B.   J-F R.   Viens P.   Gomez F.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 84-84

Elsevier

Access to resources Recommend Favorite